Halazepam is a benzodiazepine derivative that was marketed under the brand names Paxipam in the United States,[2] Alapryl in Spain,[3] and Pacinone in Portugal.

[2] Adverse effects include drowsiness, confusion, dizziness, and sedation.

Gastrointestinal side effects have also been reported including dry mouth and nausea.

[2] Pharmacokinetics and pharmacodynamics were listed in Current Psychotherapeutic Drugs published on June 15, 1998 as follows:[5] Halazepam is classified as a schedule 4 controlled substance with a corresponding code 2762 by the Drug Enforcement Administration (DEA).

However, Halazepam is not commercially available in the United States because it was withdrawn by its manufacturer for poor sales.